Management Strategy
(1)Search and exploration of Potentials
from Dormant Products
With close search of information through our own networks and SP
Advisory Board
SP investigate and identify
target products with high success potentiality but put on
the shelf and remain dormant by
their pharma companies despite POC has been
shown in the past clinical
trials.
(2)Development in the “BLUE OCEAN”
Blue Ocean Environment (smooth and quiet water with less
competition) should be
the main battle field not in
Red Ocean (bloody and competitive water) and is the best
for development, sales
promotion and access to the patients.
(3)Development by Professionals
Fully
committed in-house experts with the best expertise of their
success carrier in
the therapeutic field stratify
the final regulatory process/packages and coordinate
with PMDA at an early stage of
its development . To secure its high quality
development SP shall be in
charge of essential parts of clinical developments and
firms the routine works out to
CRO.
(4)Keep profitability now and in the future
In the area of onychomycosis, BFE1224 has no competition least in
development
(oral drugs) field and can be
expected to grow continuously for not only the
expansion of aged population
with immune suppression but patients who can not
access to two existing oral
drugs. (population ratio with onychomycosis is around
10 – 15% of all population. )